Articles from Lundbeck

Lundbeck US, the US subsidiaries of H. Lundbeck A/S., today announced the presentation of new VYEPTI® (eptinezumab-jjmr) data at the American Headache Society’s (AHS) 68th Annual Scientific Meeting, taking place June 4-7, 2026, in Orlando, Florida. The presentations will share findings from the INFUSE, DELIVER, SUNSET, and RESOLUTION trials, featuring real-world data and phase 3 clinical trial post-hoc analyses of VYEPTI and patient-reported outcomes on headache hours, brain fog and other cognitive symptoms, and dose escalation. New phase 2b data on bocunebart, an investigational drug targeting Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) for the prevention of migraine, will also be presented.

Lundbeck today presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance of evaluating the broad burden of migraine beyond headache and migraine frequency. Despite being among the most frequently reported symptoms by people living with migraine, cognition and brain fog have rarely been systematically studied. These patient-reported outcomes data highlight the opportunity to focus on elements of migraine burden that are meaningful to individuals living with migraine and report improvement of migraine-related cognitive symptoms after VYEPTI® (eptinezumab-jjmr) treatment.1

Despite being one of the leading causes of disability worldwide, migraine disease remains misunderstood, and its impact underestimated by society1. This is fueled by the risk of disease worsening and lack of recognition around the personal impact of migraine, which may preclude proper preventive care2. To help address this critical gap, Lundbeck in collaboration with six migraine patient advocacy organizations is launching the “Raise the Bar for Migraine Care” initiative this Pain Awareness Month.

Lundbeck US, the US subsidiaries of H. Lundbeck A/S, today announced it will present one oral and eight poster presentations at the 67th Annual Scientific Meeting of the American Headache Society (AHS) in Minneapolis from June 19-22, 2025. The data presentations reinforce the need to look beyond monthly migraine days (MMDs) and the importance of a holistic approach to migraine care as suggested by data from eptinezumab-jjmr post-hoc analyses.

Lundbeck US, the US subsidiaries of H. Lundbeck A/S, today announced 11 data presentations at the 66th Annual Scientific Meeting of the American Headache Society (AHS) taking place in San Diego, Calif., June 13-16, 2024. These abstracts will be featured in two oral and nine poster presentations and include new analyses of clinical data and real-world studies of VYEPTI® (eptinezumab-jjmr), an anti-CGRP monoclonal antibody for the preventive treatment of migraine. The company is also sponsoring a symposium, “Beyond Headache Days: Implications of real-world anti-CGRP findings and advancing migraine research,” on June 15 at 12:30 p.m. PT featuring findings from the real-world observational REVIEW study.

Lundbeck US, the US subsidiaries of H. Lundbeck A/S, will present new data for VYEPTI® (eptinezumab-jjmr), an anti-CGRP monoclonal antibody for the preventive treatment of migraine, including a post-hoc analysis of the Phase 3 DELIVER study that found most patients who responded to treatment within one to two doses maintained treatment response over 18 months. These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Lundbeck today announced new VYEPTI® (eptinezumab-jjmr) data will be presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS) taking place in Austin, Texas, and virtually from June 15—18, 2023. A total of nine data presentations will be featured, including real-world experience with VYEPTI, an anti-CGRP monoclonal antibody for the preventive treatment of migraine in adults, and one oral presentation highlighting disparities in migraine care and treatment from the Harris Poll Migraine Report Card Survey. In addition, Lundbeck will be sponsoring a symposium on Friday, June 16th titled “Research to Practice. Clinical implications of real-world use of an anti-CGRP mAb in high frequency migraine” led by Drs. Richard Lipton, Wade Cooper, and Amaal Starling.

Lundbeck today announced new neuroscience data will be presented at the 75th Annual Meeting of the American Academy of Neurology taking place in Boston and virtually from April 22-27, 2023. A total of 12 abstracts, including post-hoc and real-world analyses of VYEPTI® (eptinezumab-jjmr), an anti-CGRP monoclonal antibody for the preventive treatment of migraine, as well as the impact of migraine on sufferers will be featured in two oral and ten poster presentations. The company is also sponsoring a medical symposium, “Migraine: Your Patient, Your Partner. Proactive care for high-frequency, worsening disease,” focusing on studies and techniques for individualizing preventive care to improve collaboration and outcomes.

Lundbeck today announced data on VYEPTI® (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022. A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults.

Lundbeck today announced new data from an oral abstract for VYEPTI® (eptinezumab-jjmr), along with three poster presentations, are being presented at the 2022 Annual Scientific Meeting of the American Academy of Neurology (AAN), which is being held in person from April 2-7 and virtually from April 24-26. The findings are part of a post hoc analysis of one of two pivotal trials, PROMISE 2 (NCT02974153), a randomized, double-blind study that evaluated VYEPTI for the preventive treatment of chronic migraine. Results showed that a higher percentage of people with chronic migraine who experienced a reduction to 4 or fewer monthly headache days (MHDs) achieved improved health outcomes (headache impairment as measured by the 6-item Headache Impact Test (HIT-6) and improvements in Patient Global Impression of Change (PGIC)) and required less acute medication versus people with chronic migraine who experienced higher MHDs (5-9, 10-14, ≥15).1 Study participants received VYEPTI 100 mg, 300 mg, or placebo; all treatment arms were pooled for the analysis.

The full results from the RELIEF study were published today in The Journal of the American Medical Association (JAMA). VYEPTI® (eptinezumab-jjmr) met both co-primary endpoints, showing early benefit for time to headache pain freedom, and time to the absence of most bothersome symptoms (MBS), compared to placebo. Patients treated with VYEPTI experienced headache pain freedom and absence of their MBS at 2 hours post-infusion, achieving the key secondary endpoints. The RELIEF study evaluated how preventive migraine candidates may benefit from a VYEPTI infusion during an active migraine attack when administered within 1 to 6 hours of a moderate to severe migraine attack. VYEPTI is the first and only intravenous (IV) infusion approved for the preventive treatment of migraine in adults.

Lundbeck today announced that new data on migraine prevention with VYEPTI® (eptinezumab-jjmr) will be presented at the 63rd Annual Scientific Meeting of the American Headache Society (AHS), taking place virtually from June 3-6, 2021. VYEPTI is the first and only FDA-approved intravenous (IV) preventive migraine treatment for adults.